Technological advancements are the primary engine of progress in the Biosimilar Contract Manufacturing Market. Recent breakthroughs in perfusion bioreactors and automated cell culture monitoring have allowed manufacturers to achieve higher yields and consistent product quality. These technologies are not only reducing the operational costs of biologics but also making it possible to produce...